Mankind Pharma seeks CDSCO approval for Phase 1 Clinical Trials of patented anti-diabetic molecule
MKP10241 is a potent and orally administered small molecule, GPR119 agonist.
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.